Edward M Kerwin1, Selwyn Spangenthal2, Michael Zvarich3, Valerie Millar4, Renu Jain3, Kathryn Collison3, Raj Sharma5. 1. Clinical Research Institute of Southern Oregon, Medford. 2. American Health Research, Charlotte, North Carolina. 3. GlaxoSmithKline plc., Research Triangle Park, Durham, North Carolina. 4. GlaxoSmithKline plc., Uxbridge, United Kingdom. 5. Respiratory Medical Franchise, GlaxoSmithKline plc., Brentford, United Kingdom.
Abstract
BACKGROUND: Inhaler errors among patients with chronic obstructive pulmonary disease (COPD) can reduce treatment efficacy. METHODS: This randomized, open-label, crossover study evaluated correct use of ELLIPTA versus DISKUS plus HandiHaler. Participants with COPD attended at least 3 study visits (Day 1 [Visit 1], Day 28 [Visit 2], and Day 56 [Visit 3]). Inhalers contained placebo; usual maintenance medication was continued. Participants were randomized to an inhaler sequence (ELLIPTA then DISKUS plus HandiHaler, or the reverse) and preference questionnaire at Visit 1. Participants read the instructions for use in the approved prescribing information for their inhaler(s) and correct use was assessed at Visit 1 (verbal guidance provided if required). Correct use was reassessed at Visit 2, and with the next inhaler(s) at Visit 3. Primary endpoint was the proportion of participants demonstrating correct use (0 errors) with the assigned inhaler(s) after 28 days. RESULTS: A greater proportion of study participants (n = 217) correctly used ELLIPTA (96%) versus DISKUS plus HandiHaler (87%) after 28 days. The odds of demonstrating correct use with ELLIPTA were 6.88 times that of DISKUS plus HandiHaler (p < 0.001). Overall, > 99% of participants made 0 critical errors (errors leading to no or significantly reduced medication inhaled) with ELLIPTA versus 89% with DISKUS plus HandiHaler after 28 days. ELLIPTA was the patient-preferred option versus DISKUS plus HandiHaler or no preference (p < 0.001). CONCLUSIONS: Delivery of COPD maintenance therapy via ELLIPTA demonstrates higher correct use rates and lower critical error rates compared with DISKUS plus HandiHaler. JCOPDF
BACKGROUND: Inhaler errors among patients with chronic obstructive pulmonary disease (COPD) can reduce treatment efficacy. METHODS: This randomized, open-label, crossover study evaluated correct use of ELLIPTA versus DISKUS plus HandiHaler. Participants with COPD attended at least 3 study visits (Day 1 [Visit 1], Day 28 [Visit 2], and Day 56 [Visit 3]). Inhalers contained placebo; usual maintenance medication was continued. Participants were randomized to an inhaler sequence (ELLIPTA then DISKUS plus HandiHaler, or the reverse) and preference questionnaire at Visit 1. Participants read the instructions for use in the approved prescribing information for their inhaler(s) and correct use was assessed at Visit 1 (verbal guidance provided if required). Correct use was reassessed at Visit 2, and with the next inhaler(s) at Visit 3. Primary endpoint was the proportion of participants demonstrating correct use (0 errors) with the assigned inhaler(s) after 28 days. RESULTS: A greater proportion of study participants (n = 217) correctly used ELLIPTA (96%) versus DISKUS plus HandiHaler (87%) after 28 days. The odds of demonstrating correct use with ELLIPTA were 6.88 times that of DISKUS plus HandiHaler (p < 0.001). Overall, > 99% of participants made 0 critical errors (errors leading to no or significantly reduced medication inhaled) with ELLIPTA versus 89% with DISKUS plus HandiHaler after 28 days. ELLIPTA was the patient-preferred option versus DISKUS plus HandiHaler or no preference (p < 0.001). CONCLUSIONS: Delivery of COPD maintenance therapy via ELLIPTA demonstrates higher correct use rates and lower critical error rates compared with DISKUS plus HandiHaler. JCOPDF
Authors: Andrea S Melani; Marco Bonavia; Vincenzo Cilenti; Cristina Cinti; Marco Lodi; Paola Martucci; Maria Serra; Nicola Scichilone; Piersante Sestini; Maria Aliani; Margherita Neri Journal: Respir Med Date: 2011-03-02 Impact factor: 3.415
Authors: David A Lipson; Frank Barnhart; Noushin Brealey; Jean Brooks; Gerard J Criner; Nicola C Day; Mark T Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Sally Kilbride; Peter Lange; David A Lomas; Fernando J Martinez; Dave Singh; Maggie Tabberer; Robert A Wise; Steven J Pascoe Journal: N Engl J Med Date: 2018-04-18 Impact factor: 91.245
Authors: David A Lipson; Helen Barnacle; Ruby Birk; Noushin Brealey; Nicholas Locantore; David A Lomas; Andrea Ludwig-Sengpiel; Rajat Mohindra; Maggie Tabberer; Chang-Qing Zhu; Steven J Pascoe Journal: Am J Respir Crit Care Med Date: 2017-08-15 Impact factor: 21.405
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Peter A Frith; Philip J Thompson; Rajeev Ratnavadivel; Catherina L Chang; Peter Bremner; Peter Day; Christina Frenzel; Nicol Kurstjens Journal: Thorax Date: 2015-04-03 Impact factor: 9.139
Authors: Omar Sharif Usmani; Federico Lavorini; Jonathan Marshall; William Christopher Nigel Dunlop; Louise Heron; Emily Farrington; Richard Dekhuijzen Journal: Respir Res Date: 2018-01-16
Authors: Henry Chrystyn; Job van der Palen; Raj Sharma; Neil Barnes; Bruno Delafont; Anadi Mahajan; Mike Thomas Journal: NPJ Prim Care Respir Med Date: 2017-04-03 Impact factor: 2.871
Authors: Thomas M Siler; Renu Jain; Kathryn Collison; Raj Sharma; Laura Sutton; Jamie Rees; David I Bernstein Journal: PLoS One Date: 2022-08-15 Impact factor: 3.752
Authors: Philip Halverson; Joel Liem; Logan Heyes; Andy Preece; Philippe Bareille; Jamie Rees; Renu Jain; Richard H Stanford; Warren Lenney; Kathryn Collison; Raj Sharma Journal: Pediatr Pulmonol Date: 2020-11-19